Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide in Biochemical Recurrence of Prostate Cancer
NCT05753566Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide in prostate cancer (PCa), sponsored by Nanjing Drum-Tower Hospital. Started Mar 2023; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05753566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753566.